


Kent & Medway NHS & Social Care Partnership Trust - Quality Committee (QC)

Minutes of the Meeting held at 13:00 – 16:00 Tuesday, 17 November 2020 in Boardroom A, Farm Villa, Hermitage Lane, Maidstone, Kent, ME16 9PH

Members				
	Non-Executive Director (Chair of Committee)			
	Non-Executive Director (Deputy-Chair)			
	Non-Executive Director			
	Non-Executive Director			
	Executive Director of Nursing, AHPs and Quality			
	Executive Medical Director			
	Chief Operating Officer			
Deputy Director of Quality and Safety				
	Strategic Lead for Allied Health Professions			
	Chief Pharmacist			
	Director of Therapies			
In attendance				
	Minutes			
	Graduate Trainee (Min QC/20-21/119 – Readmissions Deep Dive only)			
	Head of Research and Innovation (Min QC/20-21/122 – Research and			
	Innovation Strategy only)			
	Non-Executive Director (observing)			
Apologies				
	Lead Psychologist and Care Group Director (now replaced as member			
	by Ben Smith, Director of Therapies)			


Item		Who
	The state of the s	






Page 2 of 8










Page **4** of **8**




QC/20-21/117 Quality Impact Assessment (QIA) Group - Terms of Reference The Committee received the Terms of Reference for the Quality Impact Assessment Group which had been subject to the Group's annual review. Further amendments were noted and clarification given. The Committee APPROVED the Terms of Reference for the QIA Group subject to the amendments discussed and sight of the updated version with the January meeting papers. Action – Amended QIA Terms of Reference to be added to January Committee papers for information. QC/20-21/118 High profile Serious Incidents Report – action plan progress report The Committee received the report. Three of the reported cases were brought to the Committee's attention. 2.1 Domestic homicide dating back to 2015. The independent review had been completed but not yet published. The Trust had completed all actions required but the action relating to clozapine was being checked for continued compliance. 2.5 Community death – suicide in 2018. The RCA and all five actions have been completed and closed. 2.8 Suspected suicide of twins, December 2019, high profile media case. All actions associated with this SI have been completed with 3 still to be reviewed at the care group SI Action Closure Governance Meeting before final closure approval. The Committee noted that a number of the serious incidents related to the Management of Clozapine and the following actions had been taken to improve prescribing and monitoring: An updated clozapine policy with clearer guidance around the running of the clozapine clinics in the CMHTs and monitoring particularly when patients stop smoking, develop constipation, recurrent chest infections and severe pneumonia. Ensuring patients have 6 monthly reviews by a clinician which takes into account therapeutic response and recognised side-effects as well as identifying possible relapse indicators Clozapine management standards are now included in the CMHT CliQ checks with compliance being monitored and reported New clozapine e-learning course for Doctors/ Medical Prescribers at KMPT Training of nursing staff who run the clozapine clinics by the pharmacy Training and guidance has been provided to staff in all the acute hospitals to ensure patients on clozapine are monitored safely. It is important all patients prescribed clozapine that are admitted to the Acute Trust should be and remain open to the liaison psychiatry team for ongoing monitoring for the duration of the admission. Dr Qazi has been working with Kent LMC (Local Medical Committee) and the G.Ps have agreed to support us with physical investigations for our patients. If we fill out the forms and ask patients to go to their surgeries the G.Ps will have blood tests and ECGs carried out at the surgeries. Jag Bahia

(Chief Pharmacist) has been working with the Acute Trusts so all our











_	

Signed	 (Chair
Date	